191 related articles for article (PubMed ID: 28105886)
1. Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group.
Aznar MC; Girinsky T; Berthelsen AK; Aleman B; Beijert M; Hutchings M; Lievens Y; Meijnders P; Meidahl Petersen P; Schut D; Maraldo MV; van der Maazen R; Specht L
Acta Oncol; 2017 Apr; 56(4):608-613. PubMed ID: 28105886
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
3. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations.
Fiandra C; Filippi AR; Catuzzo P; Botticella A; Ciammella P; Franco P; Borca VC; Ragona R; Tofani S; Ricardi U
Radiat Oncol; 2012 Nov; 7():186. PubMed ID: 23122028
[TBL] [Abstract][Full Text] [Related]
4. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
[TBL] [Abstract][Full Text] [Related]
5. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
6. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
Weber DC; Peguret N; Dipasquale G; Cozzi L
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
8. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
[TBL] [Abstract][Full Text] [Related]
10. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
[TBL] [Abstract][Full Text] [Related]
11. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.
Hong L; Alektiar KM; Hunt M; Venkatraman E; Leibel SA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):752-9. PubMed ID: 15183478
[TBL] [Abstract][Full Text] [Related]
13. Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis.
Fleckenstein J; Eschler A; Kremp K; Kremp S; Rübe C
Radiat Oncol; 2015 Aug; 10():178. PubMed ID: 26292716
[TBL] [Abstract][Full Text] [Related]
14. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
[TBL] [Abstract][Full Text] [Related]
15. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
[TBL] [Abstract][Full Text] [Related]
16. Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study.
Li XA; Tai A; Arthur DW; Buchholz TA; Macdonald S; Marks LB; Moran JM; Pierce LJ; Rabinovitch R; Taghian A; Vicini F; Woodward W; White JR;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):944-51. PubMed ID: 19215827
[TBL] [Abstract][Full Text] [Related]
17. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
18. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
[TBL] [Abstract][Full Text] [Related]
19. Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.
Hein PA; Gladstone DJ; Bellerive MR; Hug EB
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1540-8. PubMed ID: 16029816
[TBL] [Abstract][Full Text] [Related]
20. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck Af Rosenschöld P; Petersen PM; Specht L
Radiother Oncol; 2014 Mar; 110(3):441-7. PubMed ID: 24188865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
